Norway Renews its Support for IFFIm with US$421 Million Pledge
Norway Renews its Support for IFFIm with US$421 Million Pledge
8 May 2020
Techa Hortencia with her youngest son Jason (4 months) at Centro de Saúde do Alto Maé in Maputo, Mozambique. Jason received BCG vaccine. Photo credit Gavi/2020/Isaac Griberg
The 10-year commitment to support Gavi vaccine programmes is part of Norway’s US$ 1 billion commitment to Gavi
The 10-year commitment to support Gavi vaccine programmes is part of Norway’s US$ 1 billion commitment to Gavi
London, 8 May 2020 – Norway has committed an additional US$ 412 million over the next 10 years to the International Finance Facility for Immunisation (IFFIm), which leverages long-term donor financing to produce immediate funding for Gavi, the Vaccine Alliance.
The pledge, which Norwegian Prime Minister Erna Solberg announced at the 4 May Coronavirus Global Response pledging conference, hosted by the European Union, was part of an overall US$ 1 billion commitment to Gavi. Norway is a founding IFFIm donor and had previously committed a total of US$ 330 million since 2006.
“We’re very grateful to Norway for continuing to play an essential role in IFFIm’s future success, as it has for nearly a decade and half,” said Cyrus Ardalan, Chair of IFFIm’s Board of Directors. “Norway’s leadership has been highly instrumental in enabling Gavi and its many partners to respond effectively to the current global health crisis.”
“This is absolutely vital funding, which will help us both vaccinate millions of the most vulnerable children as well as help us deliver eventual COVID-19 vaccines to the most vulnerable,” Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance, of several 4 May pledges to Gavi, including Norway’s.
As Gavi’s long-term, flexible funding source, IFFIm is a vital component of Gavi’s funding structure. IFFIm has been instrumental in accelerating Gavi’s impact and safeguarding financial flexibility. Since 2006, IFFIm has leveraged donor pledges – including from Norway – to issue Vaccines Bonds on global capital markets, generating more than US$ 6.2 billion through 35 issuances in eight currencies. IFFIm is widely regarded as a pioneering social bond issuer, and Vaccines Bonds have enjoyed strong demand from socially responsible investors due to the clarity and focus of Gavi’s mission.
Gavi is seeking at least US$ 7.4 billion for its 2021 to 2025 programme period to protect 300 million children in 68 lower-income countries against deadly diseases. This funding will also ensure that the immunisation systems needed to deliver a COVID-19 vaccine are sustained through the pandemic. Gavi’s replenishment will conclude at the Global Vaccine Summit, hosted by the UK government on 4 June.
Correction: 12 June 2020: This news release has been updated to reflect the correct USD value of Norway’s pledge ($421 million). A previous version stated the amount as $400 million.
Share this article
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.
Reflections on IFFIm: an interview with Rachel Turner
14 November 2024